Argus analyst Jasper Hellweg indicated that Regeneron Pharmaceuticals could launch a number of potential blockbusters in the coming years, including the investigational skin cancer treatment cemiplimab next year, Investor's Business Daily reported Thursday.
Cemiplimab, a PD-1 inhibitor that is currently being investigated in five clinical studies, was granted breakthrough therapy status by the FDA in September for the treatment of cutaneous squamous cell carcinoma.
Regeneron plans to submit the therapy for approval in the US and EU next year.
Meanwhile, the drugmaker recently inked a deal with ISA Pharmaceuticals to study the experimental immunotherapy ISA101 in combination with cemiplimab for the treatment of human papillomavirus type 16-induced cancer.
"While the two companies will share clinical trials costs and exchange product supply, Regeneron will gain exclusive worldwide licensing rights for ISA101 in exchange for an upfront payment, an equity investment and future milestone payments," Hellweg noted.
"We believe that the company's financial results will benefit from potential new indications for Eylea and Praluent, as well as from increased sales of Praluent, Dupixent and Kevzara," Hellweg explained, continuing "Regeneron has the marketing and commercial ability to roll out drugs quickly, as seen in its recent product launches."
To read more NewsPoints articles, click here.